In 2014, strides were made in the care of haematological malignancies. In particular, the heterogeneity of multiple myeloma was unravelled, and new diagnostic criteria and frontline standards of care were proposed; new therapeutic approaches have been validated and approved in chronic lymphocytic leukaemia; and in chronic myeloid leukaemia, complete cytogenetic response was confirmed as the primary therapeutic end point.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
Nature Communications Open Access 18 January 2021
-
Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma
Scientific Reports Open Access 27 February 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lohr, J. G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91–101 (2014).
Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438–447 (2013).
Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 156, e538–e548 (2014).
Benboubker, L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl. J. Med. 371, 906–917 (2014).
Byrd, J. C. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371, 213–223 (2014).
Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997–1007 (2014).
Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370, 1101–1110 (2014).
Hehlmann, R. et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J. Clin. Oncol. 32, 415–422 (2014).
Branford, S. et al. Prognosis for patients with CML and >10% BCR–ABL1 after 3 months of imatinib depends on the rate of BCR–ABL1 decline. Blood 124, 511–518 (2014).
Branford, S. et al. Any BCR–ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months [abstract]. Blood 122, a254 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.F.S.-M. has acted in a consultancy or advisory capacity for Bristol–Myers Squibb, Celgene, Janssen, Millennium, MSD, Novartis and Onyx. H.M.K. has received research grants from Amgen, ARIAD, Bristol–Myers Squibb, Novartis and Pfizer.
Rights and permissions
About this article
Cite this article
San-Miguel, J., Kantarjian, H. Improved understanding of disease biology and treatment. Nat Rev Clin Oncol 12, 71–72 (2015). https://doi.org/10.1038/nrclinonc.2014.216
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.216
